In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early development programs in the fields of ...

U.S. President Donald Trump ended days of rumors and speculation when he confirmed May 12 that Marty Makary is resigning as ...

A designed chimeric virus induced broadly neutralizing antibodies against the macaque equivalent of HIV. The strategy works ...

Rigel Pharmaceuticals Inc. CEO Raul Rodriguez said breast cancer therapy Veppanu (vepdegestrant) could become his firm’s “largest product with the current label,” and other opportunities with the drug ...

Roche Holding AG secured CE marking for the Elecsys plasma phosphorylated-tau 217 blood test designed to rule in and rule out ...

Metis Techbio Co. Ltd. is seeking a potential HK$2.11 billion (US$270 million) raise through a stock sale May 13, marking the largest biotech raise on the Hong Kong Stock Exchange this year to date.

Med-tech financing activity in the first four months of 2026 reached $10.05 billion, similar to 2025’s $10.31 billion and ...

Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical ...

Rigel Pharmaceuticals Inc.’s shares (NASDAQ:RIGL) were trading at $30.18, up 15%, or $3.98, on word that the company has entered into an exclusive, global license agreement with Arvinas Inc. and ...

The initial appraisal of the first complete genome sequence of a hantavirus isolated from a patient in Switzerland who was a ...

Star Sports Medicine Co. Ltd. debuted on the Hong Kong Stock Exchange with an HK$829.55 million (US$105.86 million) IPO May 5, with shares closing about 118% higher on the first day.

Pacific, including deals and partnerships, and other news in brief: Biontech, Bioora, Boehringer Ingelheim, Capricor, Endorobotics, Nippon Shinyaku, NS Pharma, Olympus, Ribocure, Suzhou Ribo, ...